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D
espite decades of acknowledging that a loss of
insulin-producing pancreatic b-cells is central
to the disorder now referred to as type 1 di-
abetes, the speciﬁc roles for genetic suscepti-
bility, environmental factors, the immune system, and
b-cells themselves in the pathogenic processes underlying
the disorder remain unclear (1,2). Looking back over this
period, one can identify a handful of conceptualizations
that were seminal in their attempt to address this issue,
including that posited by Dr. Gian Franco Bottazzo in his
1986 article, “Death of a Beta Cell: Homicide or Suicide?”
(3). Bottazzo questioned whether the disorder’s patho-
genesis weighed more heavily (or exclusively) on pro-
cesses related to immune responsiveness (i.e., homicide)
or the fragility of b-cells leading to self-destruction (i.e.,
suicide).
Many reasons exist with respect to why we are in this
knowledge void, including the exceedingly complex nature
of type 1 diabetes, the likelihood that this disorder may
represent a disease with more than one etiology, as well as
the complex interplay of genetics, the immune system, and
the environment. One limitation in solving important
pathogenic questions in type 1 diabetes has likely been
suboptimal cross-talk among geneticists, epidemiologists,
endocrinologists, and others. Our own approach to over-
coming this limitation has been to try to increase collab-
oration between cell biologists and immunologists as
a critical step in closing knowledge gaps regarding the
disorder’s pathogenesis. The opinion put forward within
this Perspectives article by this group of authors is one
where multiple and clearly unique properties of the b-cell
appear fundamental to the loss of immune tolerance, ac-
companied by immune-mediated destruction.
WHAT DID BOTTAZZO PORTEND?
The Bottazzo article (3) was unique in its form of pre-
sentation, in that the prose represented the equivalent
workings of a legal stenographer recording the debate
between two counsels: one for the prosecution (i.e., b-cell
homicide) the other representing the defense (i.e., b-cell
suicide). More important than the means for its pre-
sentation was the evidence noted for each case. Argu-
ments for homicide included, but were not limited to,
a theoretic scenario wherein type 1 diabetes was posed to
be initiated by an ill-deﬁned environmental attack resulting
in the release of b-cell autoantigens (Fig. 1). Subsequently,
those self-antigens were thought to be scavenged by
macrophages, presented by major histocompatibility com-
plex (MHC) class II molecules (i.e., HLA-DR), leading to
the activation of helper T-cells, which would in turn activate
B-cells to produce antibodies (e.g., islet cell cytoplasmic
autoantibodies and complement-ﬁxing autoantibodies)
as well as activate killer cells and cytotoxic T-cells.
Interestingly, Bottazzo did note the potential role for
“suppressor T-lymphocytes” (i.e., a forerunner of today’s
regulatory T-cell), but left them out of the equation be-
cause of their ill-deﬁned nature at the time of his writing.
Other prosecutorial arguments included seasonality for
the disease onset, typical age of onset, and questions
related to genetic susceptibility to this disease.
This prosecution was countered by a model of b-cell
suicide, wherein the long latency period for type 1 diabetes
formation was placed alongside a series of (then) timely
genetic associations: chromosome 6 (HLA), 11 (insulin), 14
(Gm allotypes), and 2 (k light chains), allowing for regi-
mented b-cell death. Most controversial to this case was
the added consideration involving an expression of HLA
class II molecules on b-cells. This suicide model suggested
the death of a b-cell was a matter of destiny, imprinted at
the time of conception.
With a quarter century of research investigations since
the initial presentation of these arguments, taken together
with the beneﬁt of hindsight, where do we currently stand
in support of this polarizing issue of homicide versus sui-
cide? Is it an either/or proposition? Do current genetic and
physiologic insights enlighten the controversy? And ﬁnally,
how will current technologies and basic biologic insights
help to resolve this debate? Addressing these questions
forms a major part of this Perspectives article.
TYPE 1 DIABETES FROM THE PERSPECTIVE OF THE
IMMUNE RESPONSE: THE CURRENT CASE FOR HOMICIDE
Many of the concepts in the basic homicide model pre-
sented in the Bottazzo article remain intact. Indeed, a basic
tenet that remains is the notion that type 1 diabetes is
a disease of T-cells, but one highly inﬂuenced by the action
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PERSPECTIVES IN DIABETESof other components of the immune system, including
B-cells, natural killer cells, and macrophages (2).
The role of the immune response in b-cell destruc-
tion. With the caveat that no animal model (e.g., NOD
mice) captures the complexity of human type 1 diabetes,
but that some concepts can only be tested in such systems,
studies of NOD mice since the time of Bottazzo have aided
similar investigations of the immune response in human
disease. Studies in animal models of type 1 diabetes have
shown that a variety of pathogenic pathways can lead to
the immune-mediated destruction of b-cells. For example,
CD8
+ cytolytic T-cells can kill b-cells directly in a perforin-
dependent manner; but, at the same time, exposure of
b-cells to cytokines can lead to their demise. In addition,
apoptosis mediated by fatty acid synthase/fatty acid syn-
thase ligand can play an important role (4), thus illus-
trating the potentially multifaceted face of b-cell demise.
Turning to studies of humans, interferons, potentially
produced in response to local or systemic infection events,
can accelerate b-cell destruction by inducing the expres-
sion of islet antigen-presenting MHC class I molecules on
b-cells (5). These observations blend well with those of
other human studies where higher levels of MHC class I
molecules are frequently detected on b-cells (6), and in-
ﬁltration by CD8
+ T-cells in inﬂamed pancreata from type 1
diabetic patients have been found (7).
Taken collectively, multiple pathways of b-cell elimina-
tion may be operational at the same time, suggesting a re-
markable complementarity among the various pathways
targeting b-cells for destruction. This multiparameter ap-
proach to b-cell destruction by the immune system suggests
that individual immunotherapeutic treatments targeting any
one pathway may not be as successful as those aimed at the
initial target antigen recognition or active against multiple
pathways (8,9), as will be discussed later.
As was the case in the era of the Bottazzo report (3), it
remains unclear whether single or multiple primary spe-
ciﬁc antigenic targets initiate this disease. One leading
hypothesis today is that insulin itself may be the crucial
antigenic target, particularly in NOD mice, where mutating
a single amino acid of insulin peptide 9-23 prevents all
formation of diabetes (10). Further evidence of the key
role of insulin derives from genetic studies in humans
demonstrating genetic polymorphisms in the insulin gene
that alter the expression of the protein, especially in the
thymus, where central tolerance to autoantigens operates.
This being said, there is also ample evidence from T-cell
repertoire and autoantibody analyses to suggest that other
pathogenic self-antigens (e.g., GAD, insulinoma-associated
protein 2) with varying speciﬁcities may participate in the
autoimmune response (11).
Beyond this, we have also learned much since the Bot-
tazzo report about the processes of how the immune re-
sponse develops a response against various antigens over
time (i.e., intermolecular spreading of antigenicity), as well
as that within a given antigen (i.e., intramolecular or epi-
tope spreading), both of which may prove important to
type 1 diabetes formation. Indeed, we now know that the
initial antibody response in humans predominantly occurs
against the insulin or GAD molecule, with spreading over
time to other b-cell antigens. Interestingly, NOD mice
produce high levels of insulin autoantibodies, and although
NOD T-cells target multiple molecules (e.g., GAD, chro-
mogranin A), it has been harder to demonstrate autoanti-
bodies to many other T-cell targets using this animal
model, including GAD.
Novel mechanisms of antigenic processing that lead
to immune responsiveness. The initially trivial answer to
the question of why b-cells are targeted and destroyed by
the immune system was that the molecules targeted by the
immune system were merely present in b-cells. Recent
studies, however, indicate that T-cell targeting of speciﬁc
autoantigens represents a far more complex process (Fig. 2)
than once thought and may depend on tissue-speciﬁcl o -
calization and processing of a given target antigen(s). In-
deed, many examples have been found of epitopes of islet
antigens produced in b-cells that are then recognized by
speciﬁc anti-islet T-cells, and with this, multiple new con-
cepts (beyond those of the era of the Bottazzo article) need
to be considered when type 1 diabetes is viewed from the
perspective of homicide (Table 1).
First, tissue-speciﬁc cleavage may be critical to the
production of a target peptide. For instance, the neuro-
endocrine molecule chromogranin A is cleaved to produce
a speciﬁc peptide (WE14) within islets that is recognized
by the pathogenic BDC2.5 T-cell receptor (TCR) of NOD
mice in the context of pockets 5 through 9 of the I-A
g7
cMHC class II molecule, the only class II–presenting mol-
ecule in the NOD mouse (12). In contrast, other cells
FIG. 1. Bottazzo’s “Exhibit 5.” Diagram shows the hypothetical steps
leading to activation of the immune system against the b-cell. A:T h e
triggering events: 1) Environmental attack. 2) Release of autoantigens
from the b-cell. 3) The macrophage processes them on its surface mem-
brane. D/DR molecules present islet autoantigens to the helper T-cell.
4) Activation of the helper T-cell. B: Closing the circle: 1) Activation of
the B-cell to the helper T-cell. 2) Production of islet cell antibodies,
followed by antibody-dependent complement (C’) and killer cell–medi-
ated cytotoxicity. 3) Activation of the cytotoxic T-cell. Adapted (direct
prose) from Bottazzo (3), reprinted with permission from John Wiley &
Sons, Inc.
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tively produce this autoantigenic peptide. Of note, the
tissue-speciﬁc cleavage to produce the WE14 peptide
removes four N-terminal amino acids present in chro-
mogranin A that, if present, would ﬁll pockets 1 to 4 of
I-Ag7. If these four amino acids are present, they block
BDC 2.5 TCR stimulation. In addition, WE14 contains nine
COOH-terminal amino acids projecting outside the I-A
g7
binding groove, which when removed, abrogate binding
and, naturally, TCR stimulation. Thus, the speciﬁcc l e a v a g e
of chromogranin A within the b-cell is essential for the
diabetogenicity of BDC 2.5 T-cells.
Second, production of the antigenic peptide can occur in
islet b-cells, that is, not necessarily in antigen-presenting
cells (APCs) exposed to the target molecule. Unanue et al.
(13) recently found that insulin peptide B:9-23 is produced
within NOD islet b-cells, and that APCs process the pep-
tide and the whole insulin secretory granules. Only APCs
from islets are able to directly stimulate anti-B:9-23 T-cells
(without exogenous antigen), and for many anti-B:9-23
T-cell clones, provision of insulin to APCs does not lead to
stimulation, but the processed peptide needs to be pre-
sented. The B:9-23 peptide presentation is further unusual
in that it binds in a very unusual low-afﬁnity register to
I-A
g7, and binding in this register is key for presentation to
NOD anti-B:9-23 TCR (14).
Next, for type 1 diabetes to develop, it may be necessary
for T-cells to target multiple islet antigens. For example,
the CD8 T-cell clone targeting the islet-speciﬁc glucose-
6-phosphatase catalytic subunit-related protein (IGRP) is
very diabetogenic, but only when T-cells targeting insulin
peptide B:9-23 or perhaps other class II–restricted peptides
are also present. In contrast, removing IGRP autoreactivity
does not decrease progression to diabetes in NOD mice
(15). In other animal models of diabetes, however, CD8
+
T-cells speciﬁc for a single antigen can cause loss of b-cells
and diabetes (16). Taken together, it is likely that the
functional synergy between CD4
+ and CD8
+ T-cells and
their cytokine production, perhaps due to selective tissue
targets, is essential for a potent pathogenic response (in
the initial stages of) and disease development. However,
whether targeting of multiple antigens and antigenic
spreading is required for diabetes development and if so,
at which stage, is not known.
FIG. 2. Simpliﬁed model of the immune pathogenesis of type 1 diabetes. Major components include Step 1) The thymus where peptides of pe-
ripheral antigens are expressed and presented by HLA molecules on the surface of medullary thymic epithelial cells (mTECs cells) to T-cell
receptors, leading to deletion of many but not all anti-islet autoreactive T-cells. Step 2) Regulatory T-cells (Treg) and effector T-cells are both
produced, and their balance is crucial for maintaining tolerance. Innate immune activation can affect the balance in terms of activating autoim-
munity. Step 3) The b-cell itself not only produces target antigens but also modiﬁes molecules, such as chromogranin, by cleavage at critical sites,
thus creating peptides recognized by pathogenic T-cells. There is evidence that processing of molecules such as insulin within the b-cell creates
peptides that are then taken up by antigen-presenting cells either as whole, dead b-cells, or speciﬁcally, granules of b-cells, for eventual further
processing and presentation of islet peptides to effector T-cells. Step 4) The trimolecular complex, involving the MHC-presenting molecule/peptide
in the appropriate “register”/T-cell receptor recognizing both and, like a lock and key, is the essential recognition unit for adaptive organ-speciﬁc
autoimmunity. Step 5) Finally, CD4 T-cells orchestrate multiple arms of the immune system (e.g., CD8 cytotoxic T-cells, pathogenic cytokine
production), resulting in speciﬁc destruction of islet b-cells.
TABLE 1
Five recent notations supporting the importance for homicide
as a means for b-cell destruction
1. Tissue-speciﬁc cleavage appears critical to produce target
autoantigenic peptides.
2. Production of an antigenic peptide can occur directly in islet
b-cells and not merely by antigen-presenting cells exposed to
the target molecule.
3. T-cells targeting multiple islet antigens are required to cause
type 1 diabetes.
4. Post-translational modiﬁcation of peptide epitopes may be
important to their antigenicity.
5. Recognition of speciﬁc islet peptides appears to occur by
conserved sequences of T-cell receptors.
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targeting a given epitope share sequence elements. Tollefsen
et al. (17) have deﬁned TCR sequences recognizing a pep-
tide of IGRP with dominant use of Va17-Ja42 by CD8
T-cells, both in spontaneous disease of NOD mice and in
recurrent disease after islet transplantation. In addition,
the B:9-23 peptide is targeted predominantly by NOD
T-cells using the TRAV5D-4*04 germline–encoded TCR
a-chain sequence, with highly variable a-chain N regions
and variable TCR b-chains (18). Precise analysis of the
repertoire and clonality of T-cells inﬁltrating human islets
will be needed to ﬁnally answer the important question
of whether a few speciﬁc culprits are destroying b-cells
or whether multiple speciﬁcities are of comparable im-
portance.
Lastly, post-translational modiﬁcation of peptide epi-
topes could be important for fueling the process of immune
destruction. A clear example of post-translational modiﬁ-
cation of the b-cell peptide essential for T-cell auto-
reactivity does not yet exist, but other disorders where
transglutaminase modiﬁcation of gliadin is essential (19),
such as celiac disease, have illustrated the importance of
this concept.
TYPE 1 DIABETES FROM THE PERSPECTIVE OF A b-CELL:
THE CURRENT CASE FOR SUICIDE
The case for homicide presented, the converse notion
would turn to that of suicide, a notion where evidence also
continues to grow since the publication of Bottazzo’s
work. There are at least three ways in which the b-cell
might participate in its own demise:
First, the b-cell may be a very friendly target for immune
destruction. As suggested, b-cells may be vulnerable to
stress-induced changes that may occur during local infec-
tions, causing production of speciﬁc autoantigenic pep-
tides recognized by pathogenic T-cells. Second, there is
documented evidence of increased b-cell sensitivity to
cytokine-mediated killing. Indeed, b-cells appear to be
particularly sensitive to the cytokine interleukin (IL)-1b
(Fig. 3). Third, persistent changes in b-cell physiology
(e.g., hyperexpression of class I molecules) once auto-
immunity has been initiated likely enhance their sensitivity
to autoimmune destruction. Thus, it might not be surpris-
ing that b-cells within islets are predominantly destroyed
even though other cell types (e.g., islet cells producing
glucagon) express many similar antigens and survive. Fi-
nally, the islet b-cells are extremely prone to self-directed
cellular destruction because they are very sensitive to
multiple forms of endoplasmic reticulum (ER) stress, as
evidenced by mutations that affect insulin protein folding.
Indeed, the b-cell is exquisitely unique. They are the sole
source for providing insulin when needed, but also in that
their metabolic machinery is distinctively set up for gen-
erating secondary signals to control b-cell function (20).
This provides an exclusive link for metabolic homeostasis
to control cellular function; however, it might also be
the Achilles’ heel of the b-cell, as articulated in the next
section.
The b-cell’s unique metabolic regulation of insulin
production. After a meal, under normal circumstances,
the b-cell is stimulated not only to secrete insulin but also
to replenish the intracellular stores by a parallel upregu-
lation of proinsulin biosynthesis and processing (21). As
much as 20% of the total protein synthesized by a b-cell is
(pro)insulin and may occur under such conditions. The
predominant physiologically relevant nutrient to regulate
b-cell function is glucose, but certain amino acids, fatty
acids, and incretin hormones can assist in this process
(20,22). Nutrient control of b-cell function requires glucose
metabolism to generate secondary signals, such as an el-
evation in cytosolic [Ca
2+]i (23), and the carbon in glucose
is uniquely channeled from glycolysis to mitochondrial
trichloroacetic acid cycle metabolism for this purpose by
anaplerosis (20,22). As a consequence, the conglomerate
of b-cell metabolic enzymes is quite distinct from that of
other cells (Fig. 4):
First, there is a b-cell–speciﬁc isoform of glucokinase
that, together with the glucose transporter GLUT2 and low
hexokinase activity, enables the b-cell to sense circulating
glucose concentrations in the physiologic range of 2 to
20 mmol/L (19,23).
Second, b-cells are deﬁcient in lactate dehydrogenase
and plasma membrane monocarboxylate transporters, but
have a marked increase in pyruvate carboxylase activity,
all to focus channeling pyruvate into mitochondrial me-
tabolism/anaplerosis (22). Because of the lack of lactate
dehydrogenase, b-cells reoxidize NADH and maintain cel-
lular redox by highly active mitochondrial shuttles, partic-
ularly the glycerol phosphate and malate-aspartate shuttles
(22).
Third, b-cells have a low capacity to oxidize fatty acids
and relatively little pentose phosphate pathway activity
(22,24), underlining the focus of b-cells on glycolytic me-
tabolism.
Finally, b-cells appear to have a low capacity for dis-
posing of reactive oxygen species (ROS) generated from
mitochondrial metabolism, in particular H2O2 (25), which
has led some to suggest that ROS could be additional met-
abolic secondary signals for control of b-cell function (26).
Although the inimitable metabolic wiring of the b-cell
works extraordinarily well to control b-cell functions un-
der normal conditions, this might well be its undoing under
the pathologic circumstances of type 1 diabetes (Fig. 5).
Setting the stage: metabolism and hyperglycemia as
a key component for b-cells in type 1 diabetes pro-
gression. Hyperglycemia may contribute to acceleration
of type 1 diabetes through enhanced antigen exposure by
b-cells or through other mechanisms such as enhancing
their suicide. Indeed, the National Institutes of Health Di-
abetes Care and Complications Trial (DCCT) showed that
the decline in b-cell function was reduced in participants
in the group that received intensive insulin treatment
versus the control group that received standard insulin
treatment (27). At the same time, even mild persistent
hyperglycemia results in signiﬁcant depletion of insulin
stores with decreased insulin release from the remaining
b-cells, leading to a vicious cycle and ultimate deteriora-
tion of glycemic control (28,29). These observations pro-
vide a motivation underlying metabolic therapies that
provide b-cells rest to allow for insulin repletion and future
secretory responses (30). Early and subtle islet secretory
defects are an established component in at least a subset
of patients that develop type 1 diabetes (31).
Well before the onset of diabetic ketoacidosis but after
onset of autoimmunity, mild hyperglycemia may be pres-
ent. In turn, mild persistent hyperglycemia triggers ER
stress and oxidative stress in pancreatic b-cells (32), even
as inﬂammatory signaling, such as through IL-1, may also
trigger ER stress and mitochondrial stress in b-cells—
effecting a “two-hit” injury (33). Thus, metabolic con-
tributions, with their obvious linkage to type 2 diabetes,
M.A. ATKINSON AND ASSOCIATES
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(34).
An interesting result supporting such an interface
between metabolism and autoimmunity is how islet
transplantation (combined with immunomodulation), with
metabolic control recovered at least temporarily by insulin
secretion from the transplant, may be linked to neogenesis
and recovery of endogenous pancreatic b-cells (35,36).
The concept of such interplay is clinically relevant, be-
cause metabolic therapies at the time of the initial overt
type 1 diabetes often trigger a honeymoon period that
reﬂects the recovery from the acute stress-related insults
that led to the diagnosis (37). Such thinking has led many
to aim for strategies for providing enhanced b-cell function
with immunomodulation for reversal of type 1 diabetes (38).
A prototypic model for the b-cell’s unique demise in
the pathogenesis of type 1 diabetes. Proinsulin bio-
synthesis is dynamically regulated at the translational level
(39,40). Also regulated in parallel are most of the protein
components of the insulin secretory granule (ISG), many
of which, in addition to insulin itself, are major islet cell
antigens, such as IGRP, insulinoma-associated protein 2,
chromogranin A, and ZnT8, among others (40).
How could this exquisite machinery, which keeps the
b-cell well occupied even under physiologic conditions, be
derailed? Environmental factors, such as viral infections,
have long been discussed as contributing factors to type 1
diabetes pathogenesis because of the discordance in dis-
ease onset in monozygotic twins (41). Indeed, viruses must
use the host cell’s protein synthesis machinery to replicate,
FIG. 3. Activation of inﬂammatory mediators in pancreatic b-cells in type 1 diabetes. Tumor necrosis factor-a (TNF-a), IL-1b, and interferon-g
(IFN-g) are the most likely cytokines acting in synergy during inﬂammation of pancreatic b-cells, leading to the activation of a ﬁnal common
pathway, such as nuclear factor-kB (NF-kB) and, ultimately, to b-cell destruction. NF-kB can be activated by a variety of stimuli, including TNF-a,
IL-1, receptor for advanced glycation end products (RAGE), and Toll-like receptors (TLRs). IL-1b is an inﬂammatory cytokine that plays a major
role in immune-mediated b-cell destruction. Interestingly, in patients with type 2 diabetes, the IL-1 pathway blockade with an IL-1 receptor an-
tagonist (Anakinra) improved glycemic control and b-cell secretory function and resulted in a signiﬁcant reduction marker of systemic in-
ﬂammation, namely, C-reactive protein and IL-6 (56). A recent clinical study indicated that the blockade of the IL-1b pathway in type 1 diabetes
resulted in the reduced ability of mononuclear cells to trafﬁc to sites of inﬂammation (57). The latter observations provide evidence for a possible
mechanistic link between type 1 and type 2 diabetes, and additional studies are necessary to unravel the common inﬂammatory pathways involved
in the pathologic etiology of these two diseases. Compelling evidence indicates that cytokines inﬂuence the expression of inducible NO synthase
(iNOS) leading to NO production. IL-1b and IFNg, by NO synthesis, were reported to markedly decrease sarco(endo)plasmic reticulum Ca
2+
ATPase 2b (SERCA2b) protein expression, deplete Ca
2+ stores, and activate ER stress pathway, which is a potential contributing mechanism to
b-cell death. Furthermore, cytokine-induced (IL-1b + IFN-g) apoptosis of INS-1 cells appears to depend on NO production, as demonstrated by the
use of the NO dioxygenase blocker N
G-methyl-L-arginine. NO also contributes to cytokine-induced apoptosis through potentiation of Jun NH2-
terminal kinase (JNK) activity and suppression of Akt/protein kinase B. Although whether oxidative stress plays a key role in the pathogenesis of
type 1 diabetes is still being discussed, a reduced antioxidant capacity has been demonstrated in patients with type 1 diabetes compared with
healthy control subjects. To summarize the cytokine signaling, TNF-a signals through trimerized p60 receptors that interact with the TNF receptor
type 1–associated death domain protein (TRADD). Fas-associated protein with death domain (FADD) is then recruited by TRADD, thus allowing
binding of receptor-interacting protein (RIP) and TNF receptor–associated factor 2 (TRAF2) to the receptor complex. TRAF2 activates NF-kB
through NF-kB–inducing kinase (NIK)–inhibitor of kB kinase (IKK) and activates the JNK/p38 pathways. TNF-a is an inﬂammatory cytokine that
appears to be associated with a number of autoimmune disorders, including type 1 diabetes. TNF-a may activate intraislet resident macrophages,
resulting in the release of IL-1b, which generates iNOS expression and the overproduction of NO in b-cells. Alterations in the number and function
of CD4
+CD25
+ T-cells may be an additional mechanism by which TNF-a may cause type 1 diabetes in NOD mice. The role of RAGE mediated
by NF-kB has not been entirely elucidated, although RAGE may be an important intermediary in causing monocyte production of inﬂammatory
mediators such as TNF-a. It is possible that increased expression of RAGE in response to hyperglycemia may lead to activation of innate
and even adaptive immune responses and enhance b-cell destruction. After IL-1b binding to IL-1bR 1 ,M y D 8 8i sr e c r u i t e dt ot h er e c e p t o r
complex. MyD88 interacts with IL-1 receptor–associated kinase (IRAK), allowing the binding of TRAF6 to IRAK. TRAF6 causes activation of
mitogen-activated protein kinase/stress-activated protein kinase and activation of the NF-kB pathway by transforming growth factor-b–activated
kinase 1 (TAK1)–mediated activation of IKK. IL-1b also stimulates activation of protein kinase C-d (PKC-d), possibly through phospholipase
C generation of diacylglycerol. ERK, extracellular signal–regulated kinase; Jak, Janus kinase; STAT1, signal transducer and activator of
transcription-1.
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cluding the unfolded protein response and activation of
interferon pathways. Both could be detrimental for the
b-cell while attempting to combat an ongoing infection. A
virally infected b-cell would synthesize viral protein in
parallel to proinsulin and ISG proteins, and the b-cell’s
unfolded protein response could be increased in an at-
tempt to rid foreign viral proteins, while protecting the
capacity for the host cell’s normal protein biosynthesis.
However, despite the huge capacity for the b-cell secretory
pathway in proinsulin biosynthesis, the extra viral protein
synthesis may push ER stress to the point that limits the
ability to replenish stored insulin pools, and making b-cells
susceptible to apoptosis.
Also because of the high capacity of the b-cell for pro-
insulin/ISG-protein biosynthesis, ER stress is likely to
cause collateral damage to b-cell proteins, with peptides
generated that could be presented by MHC to attract an
autoimmune response, thus adding to b-cell susceptibility
for destruction. In parallel, viral peptide fragments, de-
rived from the unfolded protein response, would then be
presented by MHC class I, which is possibly upregulated
due to the antiviral interferon response (see the discussion
in the previous section) to engage the immune system and
reduce the viral infection. This could lead to direct b-cell
lysis by antiviral T-cells as well as damage to the b-cell by
upregulating interferons, leading to apoptosis in conjunc-
tion with other inﬂammatory cytokines such as IL-1b.
The unique metabolic signaling in the b-cell (Fig. 4)
could well contribute to the susceptibility for b-cell de-
struction, especially in a relative inability to dispose of
ROS (25), such as nitric oxide (NO) and associated ROS
production in the cytokine-mediated destruction of b-cells
(Fig. 3). Then, once a signiﬁcant (i.e., critical) number
of functional b-cells are lost, this metabolic susceptibil-
ity accelerates the selective b-cell destructive process.
FIG. 4. The pancreatic b-cell’s “metabolic wiring” is uniquely geared to generate secondary signals. Glucose enters the b-cell by the GLUT2
transporter, where it is phosphorylated by glucokinase and channeled to glycolysis. The combination of GLUT2 and glucokinase (with their Km
values in the mmol/L range) sense glucose in the physiologic range that is unique to only a few nutrient-sensing cells in the body. Also relatively
unique to b-cells is a negligible amount of lactate dehydrogenase (LDH) and the plasma membrane lactate/pyruvate transporter (MCT), so that the
pyruvate resulting from glycolysis is channeled to the trichloroacetic acid cycle in the mitochondria. To counter for this, there is unusually high
pyruvate carboxylase (PC) activity in b-cells to accompany pyruvate dehydrogenase (PDH). To rebalance b-cell redox in the absence of LDH/MCT,
there is an increase in mitochondrial shuttle activities, particularly the glycerol-phosphate and malate-aspartate shuttles. Mitochondrial oxidative
activity by the trichloroacetic acid cycle and electron transport chain generates [ATP] that is comparable to the glycolytic ﬂux relative to increased
circulating glucose. A byproduct of increased mitochondrial oxidative activity is a rise in oxygen radicals that can be converted to H2O2 in mi-
tochondria by superoxide dismutase-2 (SOD2). But b-cells cannot dispose of H2O2 very well because they are uniquely deﬁcient in catalase in their
peroxisomes. An increase in ATP production in b-cells leads to a rise in the adenosine 5  -triphosphate (ATP)/adenosine 5  -diphosphate (ADP) ratio
that shuts the ATP-sensitive potassium channel, which consists of the sulfonylurea receptor (SUR1) and Kir6.2 subunits. The consequential de-
creased efﬂux of K
+ results in a depolarization of the b-cell’s plasma membrane, and voltage-sensitive Ca
2+-channels open, increasing cytosolic
[Ca
2+]i. The rise in [Ca
2+]i is the major trigger to induce insulin secretory granule exocytosis for release of insulin to the circulation. The rise in
[Ca
2+]i can also activate Ca
2+/calmodulin–activated adenylate cyclases (type I, II, or VIII) to increase the cell’s [cAMP]i levels, which is an aug-
mentation signal to potentiate the Ca
2+-induced insulin secretion.
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the size of the residual pancreatic insulin pool, while
compensatory proinsulin/ISG-protein biosynthesis, which
in turn could further raise ER stress, may result in in-
creased b-cell antigen presentation by the MHC, thus
fueling a vicious cycle. In this condition, the “metabolic
wiring” of the b-cell would not help.
Glycolytic ﬂux and mitochondrial oxidation would gen-
erate increased ROS, which would contribute to oxidative
stress that enhances the b-cell apoptosis (42). Cytokine
attack from autoimmunity would increase NO production
and add to the oxidative stress and b-cell damage (43).
Formation of the disulﬁde-bonds of proinsulin also con-
tributes to ROS, so increased proinsulin biosynthesis itself
is likely to add to ER stress and also to oxidative stress.
Finally, because the metabolic enzyme makeup of b-cells
is designed to generate secondary signals, chronically in-
creased glycolytic ﬂu xc o u l dl e a dt os u c ha ne l e v a t i o no f
intracellular signals such as [Ca
2+]i so that the normal
buffering capacity to handle ﬂuxes of [Ca
2+]i is overcome
and it becomes cytotoxic (44). Try as it may to rectify the
situation by producing more insulin, the unique metabolic
regulation of the b-cell function tends to further its own
demise (Fig. 5).
Nonetheless, hyperglycemia alone is not sufﬁcient to
induce b-cell death but can impart dysfunction (45). Rather
modest hyperglycemia, together with cytokine-mediated
oxidative and ER stress, will exacerbate b-cell death and
dysfunction. The contribution from hyperglycemia in ac-
celerating this b-cell destructive process could be impor-
tant when considering the recovery of b-cell function that
occurs in the honeymoon period for many new-onset type
1 diabetic patients, once the hyperglycemia is treated.
BRIDGING THE GAP: b-CELL HOMICIDE AND SUICIDE
TAKEN TOGETHER
More recently, it has become apparent that the onset of
type 1 diabetes may not be solely a consequence of
irreversible b-cell death. Loss of insulin production more
likely results from a combination of b-cell destruction
alongside partially reversible loss of b-cell function caused
by inﬂammatory cytokines. In support of this notion,
studies of human pancreata suggest that small numbers of
insulin-positive b-cells are present in many patients with
established type 1 diabetes, suggesting that b-cells can
survive but are not able to secrete sufﬁcient insulin to
overcome hyperglycemia. In addition, some recent im-
mune intervention trials observed rapid recovery of b-cell
function that was too rapid to be explained by b-cell rep-
lication or neogenesis. For example, Couri et al. (46)
achieved at least temporary insulin independence and in-
creased C-peptide in most type 1 diabetic patients who
were treated with a nonmyeloablative bone marrow trans-
plant after strong immunosuppression. Thus, aborting the
inﬂammatory and autoreactive response in conjunction
with relieving metabolic stress might be sufﬁcient to re-
store function in surviving b-cells. Crucial aspects that
need to be studied in the future include determining the
frequency of metabolically inactive surviving b-cells and
identifying the pathways within b-cells that are affected by
inﬂammatory immune mediators in conjunction with met-
abolic stress.
This is a signiﬁcant issue, because mature b-cells have
very little ability to proliferate and make up for the loss
caused by an autoimmune insult. Speciﬁcally, although
b-cell proliferation is readily detectable in children, new
evidence suggests the proliferative capacity is already
markedly reduced during early adolescence (47). This re-
duction is partly due to the increased expression of the
cyclin-dependent kinase inhibitor p16 in aging b-cells that
is partly mediated by components of the polycomb group
of histone methyltransferases (48,49). Thus, even when the
immune insult is blocked, it may be critical to develop
approaches to induce the proliferation of remaining b-cells
in older patients with long-standing type 1 diabetes to re-
store normoglycemia.
FIG. 5. The progressive state of b-cell dysfunction in type 1 diabetes—a model for stages of depression? As noted in the text, increasing data
support a model of progressive b-cell dysfunction in type 1 diabetes. Meaning, from the activities of a variety of “stressors,” (e.g., inﬂammation,
glucolipotoxicity, ER stress, etc.), b-cells move from a state of normalcy to a “stressed” state by a process that depletes the insulin storage pool.
Therefore, b-cells proceed to a state where dysfunctional insulin secretion occurs, along with expansion and distortion of the ER. The end stage is
one of “assisted suicide,” where the immunologic parameters, when combined with unique susceptibilities inherent to b-cells, lead to their ulti-
mate demise.
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can be generated from progenitor tissue. Indeed, studies in
mice that have undergone pancreatic injury have demon-
strated that other cell types, including duct or duct-asso-
ciated cells, can reactivate the endocrine program and
generate insulin-producing cells (50). Recent efforts also
suggest that the immune system itself may be important in
this regeneration process. Thus, future studies will have to
address whether the b-cells found in patients with long-
standing type 1 diabetes are derived from the few surviving
b-cells that have escaped the immune insult or whether
they have formed by neogenesis from a non–b-cell pop-
ulation. Importantly, understanding the origin of the b-cells
present in type 1 diabetic patients might inﬂuence the
choice of immune regulatory drug therapies to maximize
islet regeneration and increase b-cell mass, while at the
same time halting the immune assault.
Finally, it is likely that physiologic changes of b-cells in
response to autoimmunity or unknown environmental
factors may be critical to perpetuating islet autoimmunity.
Studies of pancreatic sections from patients with both
new-onset and a subset of patients with long-term type 1
diabetes reveal b-cell destruction in a lobular pattern, with
some regions of the pancreas where all islets contain
b-cells, whereas in other regions, all b-cells have been
destroyed. As the number of whole pancreata from de-
ceased donors with type 1 diabetes become more readily
available, such as those in the Juvenile Diabetes Research
Foundation (JDRF) Network for Pancreatic Donors with
Diabetes (nPOD) resource (histology available online for
research viewing at www.jdrfnpod.org), it is becoming
clear that the degree of insulitis of most patients with type
1 diabetes is not only lobular but is also much less than
that present in the NOD mouse or the BB rat animal
models. This may relate to the usual very slow progression
of b-cell loss in humans, occurring over years.
The nPOD resource also highlights the existence of
heterogeneity of pancreatic pathology for patients who
were diagnosed with type 1 diabetes. A subset of the
pancreata from patients lacking islet autoantibodies or
high-risk HLA have no pseudoatrophic islets (islets lacking
all b-cells, typically associated with type 1A diabetes) but
rather have decreased numbers of b-cells per islet rather
than increased islets lacking all b-cells (51). Both for
humans (of pancreata with pseudoatrophic islets) and the
NOD mouse, the surviving b-cells are not normal and
hyperexpress MHC class I alleles and the survivin molecule.
In addition, hyperexpression of MHC class I alleles is seen in
a lobular fashion up to 8 years after diagnosis, independently
of islet inﬁltration (51). Unfortunately, the speciﬁc initiators
of increased expression of MHC class I molecules on b-cells
are not yet clear (see our earlier discussion).
USING KNOWLEDGE OF HOMICIDE AND SUICIDE OF
b-CELLS TO DEVELOP THERAPIES FOR TYPE 1 DIABETES
Taken collectively, these concepts suggest how, through
targeting of mechanisms of homicide and suicide, thera-
pies seeking to prevent or reverse type 1 diabetes could be
optimized (Fig. 5). This would include combining therapies
that have already shown some degree of promise in mod-
ulating the immunologic attack, such as antibodies against
lymphoid cell subsets (e.g., anti-CD3 or anti-CD20 mono-
clonal antibodies) or antigen-speciﬁc therapies (e.g., alum/
GAD65 immunization), with agents that would preserve b-cell
function (i.e., prevent suicide) or induce their replication
(Fig. 6) (52–55). Indeed, by blocking inﬂammatory path-
ways together with modulation of adaptive immunity,
homicide and suicide might be prevented and the direct
effects of the immune therapy might be improved.
Furthermore, these concepts suggest a potential role for
metabolic control to enhance any effect of an immune
modulator. The honeymoon that is experienced soon after
clinical presentation in patients with type 1 diabetes may
indeed reﬂect a reversal of the pathways of suicide that
have been described. Unfortunately, this alone is not suf-
ﬁcient to prevent autoimmunity, because deterioration in
insulin secretion invariably occurs. This is consistent with
the modest effect of blockade of anti-inﬂammatory medi-
ators such as IL-1b and tumor necrosis factor-a alone on
progression of diabetes. Nonetheless, when combined with
an immune therapy, the effects may be synergistic and
long lasting.
In referring back to the question once posed by G.
Franco Bottazzo some 25 years ago, is the death of a b-cell
in the pathogenesis of diabetes homicide or suicide? given
what we have learned about the immune response and the
b-cell, our belief is that type 1 diabetes appears to be
a case of (immune) self-assisted homicide.
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